Please ensure Javascript is enabled for purposes of website accessibility

After Plummeting More Than 23%, Is Exelixis a Buy?

By Alex Carchidi - Jul 9, 2021 at 6:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

On June 28, shareholders in the cancer therapeutics company Exelixis (EXEL 1.30%) got a nasty shock: Its stock price plunged by more than 23% after it delivered worse-than-expected data from a phase 3 clinical trial. The company's flagship renal cell carcinoma drug, Cabometyx, was being investigated as part of a combination therapy for advanced hepatocellular carcinoma. But the trial failed to conclusively prove that Cabometyx improved patients' overall survival prospects, per an interim analysis.

What's more, Exelixis doesn't expect that these results will change when it conducts a final analysis after the trial concludes next year. 

As a result, it's unlikely that Cabometyx will get regulatory approval for the new indication, and the other ongoing trials involving the drug will have even higher stakes now that its efficacy has been called into question. After such a setback, investors are right to be skittish about Exelixis' revenue growth prospects -- but there's no reason for them to be running for the hills.

An investor looks pensive as he ponders a readout from a screen.

Image source: Getty Images.

Things aren't as bad as they seem

Despite the disappointing new results for Cabometyx, it's important to look at Exelixis in a broader context. As of the first quarter of 2021, Cabometyx held a 36% share of the market for tyrosine kinase inhibitors that treat renal cell carcinoma, making it the most used drug in that application. To win that market share, it unseated leading competitors by securing a larger volume of new prescriptions. That means the drug is gaining traction, so investors can count on modest increases in recurring revenue for the time being. For reference, the company's revenue grew by 19.1% year over year in Q1, which isn't half bad given that Cabometyx first hit the market in 2016.

^SPX Chart
Data by YCharts.

Importantly, Exelixis isn't anywhere near being done with developing Cabometyx. The company has a handful of late-stage clinical trials underway that are investigating its effectiveness in indications such as non-small cell lung cancer. And, because the drug is already FDA approved, the work to expand its market could potentially bear fruit quickly. 

The company has promising candidates in its pipeline, too. Though development is still at an early stage, its XL092 program targets many of the same conditions as Cabometyx, and it could also eventually be used to treat endometrial cancer. So, while Exelixis may be a one-trick pony for the moment, as all of its products are different formulations of the active ingredient in Cabometyx, management is working to ensure that it won't remain that way forever.

Tread carefully when betting on a turnaround

While the company clearly has growth opportunities, there are a few issues that should give potential investors pause.

In Q1 2021, its earnings collapsed as a result of rapidly rising operating expenses, which grew by 58% year over year. Driving this were sharp increases in its cost of goods sold (COGS), research and development, and selling, general, and administrative (SG&A) expenses. Right now, Exelixis has a profit margin of around 6.3%, which means that it might need to draw down on the $1.19 billion in cash it has on the balance sheet to fund operations if it has another bad quarter. So, independent of the weak clinical trial results for Cabometyx, the company's performance is weakening.

Still, the market probably overreacted to the trial results. While it's true that shareholders can probably expect somewhat less revenue to roll in if Cabometyx ends up being approved for another new indication despite the unfavorable data, nothing has changed about the business or its ability to develop cancer therapies effectively. And remember, its revenue is still growing. While I wouldn't be comfortable with betting the farm on a turnaround, Exelixis stock is still worth buying because it's likely cheaper than it should be thanks to the market's short-term thinking.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$19.48 (1.30%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.